|
As evaluated in IARC Monographs Volumes 1-100A
This list contains all hazards evaluated to date, according
to the type of hazard posed and to the type of exposure.
Where appropriate, chemical abstract numbers are given [in
square brackets]. For details of the evaluation, the relevant
Monograph should be consulted (volume number given in round
brackets, followed by year of publication of latest evaluation).
Use a free-text search to find a particular compound.
Group 1: Carcinogenic to humans (108)
Agents and groups of agents
4-Aminobiphenyl [92-67-1] (Vol. 1, Suppl. 7, Vol. 99; in
preparation)
Aristolochic acid (Vol. 82, Vol. 100A; in preparation)
(NB: Overall evaluation upgraded from 2A to 1 based on mechanistic
and other relevant data)
Arsenic [7440-38-2] and arsenic compounds (Vol. 23, Suppl.
7; 1987)
(NB: This evaluation applies to the group of compounds as
a whole and not necessarily to all individual compounds
within the group)
Asbestos [1332-21-4] (Vol. 14, Suppl. 7; 1987)
Azathioprine [446-86-6] (Vol. 26, Suppl. 7, Vol. 100A;
in preparation)
Benzene [71-43-2] (Vol. 29, Suppl. 7; 1987)
Benzidine [92-87-5] (Vol. 29, Suppl. 7, Vol. 99; in preparation)
Benzo[a]pyrene [50-32-8] (Vol. 32, Suppl. 7, Vol.
92; in preparation)
(NB: Overall evaluation upgraded from 2B to 1 based on mechanistic
and other relevant data)
Beryllium [7440-41-7] and beryllium compounds (Vol. 58;
1993)
N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine)
[494-03-1] (Vol. 4, Suppl. 7, Vol. 100A; in preparation)
Bis(chloromethyl)ether [542-88-1] and chloromethyl methyl
ether [107-30-2] (technical-grade)
(Vol. 4, Suppl. 7; 1987)
1,3-Butadiene [106-99-0] (Vol. 71, Vol. 97; 2008)
1,4-Butanediol dimethanesulfonate (Busulphan; Myleran)
[55-98-1] (Vol. 4, Suppl. 7, Vol. 100A; in preparation)
Cadmium [7440-43-9] and cadmium compounds (Vol. 58; 1993)
Chlorambucil [305-03-3] (Vol. 26, Suppl. 7, Vol. 100A;
in preparation)
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
(Methyl-CCNU; Semustine) [13909-09-6] (Suppl. 7, Vol. 100A;
in preparation)
Chromium[VI] (Vol. 49; 1990)
Cyclophosphamide [50-18-0] [6055-19-2] (Vol. 26, Suppl.
7, Vol. 100A; in preparation)
Cyclosporine [79217-60-0] (Vol. 50, Vol. 100A; in preparation)
Diethylstilboestrol [56-53-1] (Vol. 21, Suppl. 7, Vol.
100A; in preparation)
Dyes metabolized to benzidine (Vol. 99; in preparation)
(NB: Overall evaluation upgraded to Group 1 based on mechanistic
and other relevant data)
Epstein-Barr virus (Vol. 70; 1997)
Erionite [66733-21-9] (Vol. 42, Suppl. 7; 1987)
Estrogen-progestogen menopausal therapy (combined) (Vol.
72, Vol. 91, Vol. 100A; in preparation)
Estrogen-progestogen oral contraceptives (combined) (Vol.
72, Vol. 91, Vol. 100A; in preparation)
(NB: There is also convincing evidence in humans that these
agents confer a protective effect against cancer in the
endometrium and ovary)
Estrogens, nonsteroidal (Suppl. 7, Vol. 100A; in preparation)
(NB: This evaluation applies to the group of compounds as
a whole and not necessarily to all individual compounds
within the group)
Estrogens, steroidal (Suppl. 7, Vol. 100A; in preparation)
(NB: This evaluation applies to the group of compounds as
a whole and not necessarily to all individual compounds
within the group)
Estrogen therapy, postmenopausal (Vol. 72, Vol. 100A; in
preparation)
Ethanol [64-17-5] in alcoholic beverages (Vol. 96; in preparation)
Ethylene oxide [75-21-8] (Vol. 60, Vol. 97; 2008)
(NB: Overall evaluation upgraded from 2A to 1 based on mechanistic
and other relevant data)
Etoposide [33419-42-0] (Vol. 76, Vol. 100A; in preparation)
(NB: Overall evaluation upgraded from 2A to 1 based on mechanistic
and other relevant data)
Etoposide in combination with cisplatin and bleomycin (Vol.
76, Vol. 100A; in preparation)
Formaldehyde [50-00-0] (Vol. 88; 2006)
Gallium arsenide [1303-00-0] (Vol. 86; 2006)
[Gamma Radiation: see X- and Gamma (g)-Radiation]
Helicobacter pylori (infection with) (Vol. 61; 1994)
Hepatitis B virus (chronic infection with) (Vol. 59; 1994)
Hepatitis C virus (chronic infection with) (Vol. 59; 1994)
Human immunodeficiency virus type 1 (infection with) (Vol.
67; 1996)
Human papillomavirus types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59 and 66 (Vol. 64, Vol. 90; 2007)
(NB: The HPV types that have been classified as carcinogenic
to humans can differ by an order of magnitude in risk
for cervical cancer)
Human T-cell lymphotropic virus type I (Vol. 67; 1996)
Melphalan [148-82-3] (Vol. 9, Suppl. 7, Vol. 100A; in preparation)
8-Methoxypsoralen (Methoxsalen) [298-81-7] plus ultraviolet
A radiation (Vol. 24, Suppl. 7,
Vol. 100A; in preparation)
Methylenebis(chloroaniline) (MOCA) [101-14-4] (Vol. 57,
Vol. 99; in preparation)
(NB: Overall evaluation upgraded to Group 1 based on mechanistic
and other relevant data)
MOPP and other combined chemotherapy including alkylating
agents (Suppl. 7, Vol. 100A; in preparation)
Mustard gas (Sulfur mustard) [505-60-2] (Vol. 9, Suppl.
7; 1987)
2-Naphthylamine [91-59-8] (Vol. 4, Suppl. 7, Vol. 99; in
preparation)
Neutrons (Vol. 75; 2000)
(NB: Overall evaluation upgraded from 2B to 1 with supporting
evidence from other relevant data)
Nickel compounds (Vol. 49; 1990)
N'-Nitrosonornicotine (NNN) [16543-55-8] and 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone
(NNK) [64091-91-4] (Vol. 37, Suppl. 7, Vol. 89; 2007)
(NB: Overall evaluation upgraded from 2B to 1 based on mechanistic
and other relevant data)
[Oestrogen: see Estrogen]
Opisthorchis viverrini (infection with) (Vol. 61;
1994)
[Oral contraceptives, combined estrogen-progestogen: see
Estrogen-progestogen oral contraceptives (combined)]
Oral contraceptives, sequential (Suppl. 7, Vol. 100A; in
preparation)
Phenacetin [62-44-2] (Vol. 24, Suppl. 7, Vol. 100A; in
preparation)
(NB: Overall evaluation upgraded from 2A to 1 with supporting
evidence from other relevant data)
Phosphorus-32, as phosphate (Vol. 78; 2001)
Plutonium-239 and its decay products (may contain plutonium-240
and other isotopes), as aerosols (Vol. 78; 2001)
Radioiodines, short-lived isotopes, including iodine-131,
from atomic reactor accidents and nuclear weapons detonation
(exposure during childhood) (Vol. 78; 2001)
Radionuclides, a-particle-emitting,
internally deposited (Vol. 78; 2001)
(NB: Specific radionuclides for which there is sufficient
evidence for carcinogenicity to humans are also listed individually
as Group 1 agents)
Radionuclides, b-particle-emitting,
internally deposited (Vol. 78; 2001)
(NB: Specific radionuclides for which there is sufficient
evidence for carcinogenicity to humans are also listed individually
as Group 1 agents)
Radium-224 and its decay products (Vol. 78; 2001)
Radium-226 and its decay products (Vol. 78; 2001)
Radium-228 and its decay products (Vol. 78; 2001)
Radon-222 [10043-92-2] and its decay products (Vol. 43,
Vol. 78; 2001)
Schistosoma haematobium (infection with) (Vol. 61;
1994)
Silica [14808-60-7], crystalline (inhaled in the form of
quartz or cristobalite from occupational sources) (Vol.
68; 1997)
Solar radiation (Vol. 55; 1992)
Talc containing asbestiform fibres (Vol. 42, Suppl. 7;
1987)
Tamoxifen [10540-29-1] (Vol. 66, Vol. 100A; in preparation)
(NB: There is also conclusive evidence that tamoxifen reduces
the risk of contralateral breast cancer)
2,3,7,8-Tetrachlorodibenzo-para-dioxin [1746-01-6]
(Vol. 69; 1997)
(NB: Overall evaluation upgraded from 2A to 1 with supporting
evidence from other relevant data)
Thiotepa [52-24-4] (Vol. 50, Vol. 100A; in preparation)
Thorium-232 and its decay products, administered intravenously
as a colloidal dispersion of thorium-232 dioxide (Vol. 78;
2001)
ortho-Toluidine [95-53-4] (Vol. 77, Vol. 99; in
preparation)
Treosulfan [299-75-2] (Vol. 26, Suppl. 7, Vol. 100A; in
preparation)
Vinyl chloride [75-01-4] (Vol. 19, Suppl. 7, Vol. 97; 2008)
X- and Gamma (g)-Radiation (Vol.
75; 2000)
Mixtures
Aflatoxins (naturally occurring mixtures of) [1402-68-2]
(Vol. 56, Vol. 82; 2002)
Alcoholic beverages (Vol. 44, Vol. 96; in preparation)
Areca nut (Vol. 85; 2004)
(NB: Overall evaluation based on human data, animal data,
and mechanistic and other relevant data)
Betel quid with tobacco (Vol. 85; 2004)
Betel quid without tobacco (Vol. 85; 2004)
Coal-tar pitches [65996-93-2] (Vol. 35, Suppl. 7; 1987)
Coal-tars [8007-45-2] (Vol. 35, Suppl. 7; 1987)
Household combustion of coal, indoor emissions from (Vol.
95; in preparation)
Mineral oils, untreated and mildly treated (Vol. 33, Suppl.
7; 1987)
Phenacetin, analgesic mixtures containing (Suppl. 7, Vol.
100A; in preparation)
Plants containing aristolochic acid (Vol. 82, Vol. 100A;
in preparation)
Salted fish (Chinese-style) (Vol. 56; 1993)
Shale-oils [68308-34-9] (Vol. 35, Suppl. 7; 1987)
Soots (Vol. 35, Suppl. 7; 1987)
Tobacco, smokeless (Vol. 37, Suppl. 7, Vol. 89; 2007)
Wood dust (Vol. 62; 1995)
Exposure circumstances
Aluminium production (Vol. 34, Suppl. 7; 1987)
Arsenic in drinking-water (Vol. 84; 2004)
Auramine production (Suppl. 7, Vol. 99; in preparation)
Boot and shoe manufacture and repair (Vol. 25, Suppl. 7;
1987)
Chimney sweeping (Vol. 92; in preparation)
Coal gasification (Vol. 34, Suppl. 7, Vol. 92; in preparation)
Coal-tar distillation (Vol. 92; in preparation)
Coke production (Vol. 34, Suppl. 7, Vol. 92; in preparation)
Furniture and cabinet making (Vol. 25, Suppl. 7; 1987)
Haematite mining (underground) with exposure to radon (Vol.
1, Suppl. 7; 1987)
Involuntary smoking (exposure to secondhand or 'environmental'
tobacco smoke) (Vol. 83; 2004)
Iron and steel founding (Vol. 34, Suppl. 7; 1987)
Isopropyl alcohol manufacture (strong-acid process) (Suppl.
7; 1987)
Magenta production (Vol. 57, Vol. 99; in preparation)
Painter (occupational exposure as a) (Vol. 47, Vol. 98;
in preparation)
Paving and roofing with coal-tar pitch (Vol. 92; in preparation)
Rubber industry (Vol. 28, Suppl. 7; 1987)
Strong-inorganic-acid mists containing sulfuric acid (occupational
exposure to) (Vol. 54; 1992)
Tobacco smoking and tobacco smoke (Vol. 83; 2004)
Group 2A: Probably carcinogenic to humans (63)
Agents and groups of agents
Acrylamide [79-06-1] (Vol. 60; 1994)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Adriamycin [23214-92-8] (Vol. 10, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Androgenic (anabolic) steroids (Suppl. 7; 1987)
Azacitidine [320-67-2] (Vol. 50; 1990)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Bischloroethyl nitrosourea (BCNU) [154-93-8] (Vol. 26,
Suppl.7; 1987)
Captafol [2425-06-1] (Vol. 53; 1991)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Chloramphenicol [56-75-7] (Vol. 50; 1990)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
a-Chlorinated toluenes (benzal
chloride [98-87-3], benzotrichloride [98-07-7], benzyl chloride
[100-44-7]) and benzoyl chloride [98-88-4] (combined exposures)
(Vol. 29, Suppl. 7, Vol. 71; 1999)
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) [13010-47-4](Vol.
26, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
4-Chloro-ortho-toluidine [95-69-2] (Vol. 77, Vol.
99; in preparation)
Chlorozotocin [54749-90-5] (Vol. 50; 1990)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Cisplatin [15663-27-1] (Vol. 26, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Clonorchis sinensis (infection with) (Vol. 61; 1994)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Cyclopenta[cd]pyrene [27208-37-3] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Dibenz[a,h]anthracene [53-70-3] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Dibenzo[a,l]pyrene [191-30-0] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Diethyl sulfate [64-67-5] (Vol. 54, Vol. 71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Dimethylcarbamoyl chloride [79-44-7] (Vol. 12, Suppl. 7,
Vol. 71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
1,2-Dimethylhydrazine [540-73-8] (Vol. 4, Suppl. 7, Vol.
71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Dimethyl sulfate [77-78-1] (Vol. 4, Suppl. 7, Vol. 71;
1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Epichlorohydrin [106-89-8] (Vol. 11, Suppl. 7, Vol. 71;
1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Ethyl carbamate (urethane) [51-79-6] (Vol. 7, Suppl. 7,
Vol. 96; in preparation)
(NB: Overall evaluation upgraded from 2B to 2A based on
mechanistic and other relevant data)
Ethylene dibromide [106-93-4] (Vol. 15, Suppl. 7, Vol.
71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
N-Ethyl-N-nitrosourea [759-73-9] (Vol. 17,
Suppl.7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Glycidol [556-52-5] (Vol. 77; 2000)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Indium phosphide [22398-80-7] (Vol. 86; 2006)
(NB: Overall evaluation upgraded from 2B to 2A)
IQ (2-Amino-3-methylimidazo[4,5-f]quinoline) [76180-96-6]
(Vol. 56; 1993)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Kaposi's sarcoma herpesvirus/human herpesvirus 8 (Vol.
70; 1997)
Lead compounds, inorganic (Vol. 87; 2006)
5-Methoxypsoralen [484-20-8] (Vol. 40, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Methyl methanesulfonate [66-27-3] (Vol. 7, Suppl. 7, Vol.
71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
N-Methyl-N´-nitro-N-nitrosoguanidine(MNNG)
[70-25-7] (Vol. 4, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
N-Methyl-N-nitrosourea [684-93-5] (Vol. 17,
Suppl.7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Nitrate or nitrite (ingested) under conditions that result
in endogenous nitrosation (Vol. 94; in preparation)
Nitrogen mustard [51-75-2] (Vol. 9, Suppl. 7; 1987)
N-Nitrosodiethylamine [55-18-5] (Vol. 17, Suppl.
7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
N-Nitrosodimethylamine [62-75-9] (Vol. 17, Suppl.
7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Procarbazine hydrochloride [366-70-1] (Vol. 26, Suppl.
7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Styrene-7,8-oxide [96-09-3] (Vol. 60; 1994)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Teniposide [29767-20-2] (Vol. 76; 2000)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Tetrachloroethylene [127-18-4] (Vol. 63; 1995)
Trichloroethylene [79-01-6] (Vol. 63; 1995)
1,2,3-Trichloropropane [96-18-4] (Vol. 63; 1995)
Tris(2,3-dibromopropyl) phosphate [126-72-7] (Vol. 20,
Suppl. 7, Vol. 71;1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Ultraviolet radiation A (Vol. 55; 1992)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Ultraviolet radiation B (Vol. 55; 1992)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Ultraviolet radiation C (Vol. 55; 1992)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
[Urethane: see Ethyl carbamate]
Vinyl bromide [593-60-2] (Vol. 39, Suppl. 7, Vol. 71, Vol.
97; 2008)
(NB: (1) Overall evaluation upgraded from 2B to 2A based
on mechanistic and other relevant data;
(2) For practical purposes, vinyl bromide should be considered
to act similarly to the human carcinogen vinyl chloride.)
Vinyl fluoride [75-02-5] (Vol. 63, Vol. 97; 2008)
(NB: (1) Overall evaluation upgraded from 2B to 2A based
on mechanistic and other relevant data;
(2) For practical purposes, vinyl fluoride should be considered
to act similarly to the human carcinogen vinyl chloride.)
Mixtures
Creosotes [8001-58-9] (Vol. 35, Suppl. 7, Vol. 92; in preparation)
Diesel engine exhaust (Vol. 46; 1989)
High-temperature frying, emissions from (Vol. 95; in preparation)
Hot mate (Vol. 51; 1991)
Household combustion of biomass fuel (primarily wood),
indoor emissions from (Vol. 95; in preparation)
Non-arsenical insecticides (occupational exposures in spraying
and application of) (Vol. 53; 1991)
Polychlorinated biphenyls [1336-36-3] (Vol. 18, Suppl.
7; 1987)
Exposure circumstances
Art glass, glass containers and pressed ware (manufacture
of) (Vol. 58; 1993)
Carbon electrode manufacture (Vol. 92; in preparation)
Cobalt metal with tungsten carbide (Vol. 86; 2006)
Hairdresser or barber (occupational exposure as a) (Vol.
57, Vol. 99; in preparation)
Petroleum refining (occupational exposures in) (Vol. 45;
1989)
Shiftwork that involves circadian disruption (Vol. 98;
in preparation)
Sunlamps and sunbeds (use of) (Vol. 55; 1992)
Group 2B: Possibly carcinogenic to humans (248)
Agents and groups of agents
A-a-C (2-Amino-9H-pyrido[2,3-b]indole)
[26148-68-5] (Vol. 40, Suppl. 7; 1987)
Acetaldehyde [75-07-0] (Vol. 36, Suppl. 7, Vol. 71; 1999)
Acetamide [60-35-5] (Vol. 7, Suppl. 7, Vol. 71; 1999)
Acrylonitrile [107-13-1] (Vol. 71; 1999)
AF-2 [2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide] [3688-53-7]
(Vol.31, Suppl. 7; 1987)
Aflatoxin M1 [6795-23-9] (Vol. 56; 1993)
para-Aminoazobenzene [60-09-3] (Vol. 8, Suppl. 7;
1987)
ortho-Aminoazotoluene [97-56-3] (Vol. 8, Suppl.
7; 1987)
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole [712-68-5]
(Vol. 7, Suppl. 7; 1987)
Amsacrine [51264-14-3] (Vol. 76; 2000)
ortho-Anisidine [90-04-0] (Vol. 73; 1999)
Antimony trioxide [1309-64-4] (Vol. 47; 1989)
Aramite® [140-57-8] (Vol. 5, Suppl. 7; 1987)
Auramine [492-80-8] (technical-grade) (Vol. 1, Suppl. 7,
Vol. 99; in preparation)
Azaserine [115-02-6] (Vol. 10, Suppl. 7; 1987)
Aziridine [151-56-4] (Vol. 9, Suppl. 7, Vol. 71; 1999)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Benz[j]aceanthrylene [202-33-5] (Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
mechanistic and other relevant data)
Benz[a]anthracene [56-55-3] (Vol. 32, Suppl. 7,
Vol. 92; in preparation)
Benzo[b]fluoranthene [205-99-2] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
Benzo[j]fluoranthene [205-82-3] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
Benzo[k]fluoranthene [207-08-9] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
Benzofuran [271-89-6] (Vol. 63; 1995)
Benzo[c]phenanthrene [195-19-7] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Benzyl violet 4B [1694-09-3] (Vol. 16, Suppl. 7; 1987)
2,2-Bis(bromomethyl)propane-1,3-diol [3296-90-0] (Vol.
77; 2000)
Bleomycins [11056-06-7] (Vol. 26, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Bracken fern (Vol. 40, Suppl. 7; 1987)
Bromodichloromethane [75-27-4] (Vol. 52, Vol. 71; 1999)
Butylated hydroxyanisole (BHA) [25013-16-5] (Vol. 40, Suppl.
7;1987)
b-Butyrolactone
[3068-88-0] (Vol. 11, Suppl. 7, Vol. 71; 1999)
Caffeic acid [331-39-5] (Vol. 56; 1993)
Carbon black [1333-86-4] (Vol. 65, Vol. 93; in preparation)
Carbon tetrachloride [56-23-5] (Vol. 20, Suppl. 7, Vol.
71; 1999)
Catechol [120-80-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)
Chlordane [57-74-9] (Vol. 79; 2001)
Chlordecone (Kepone) [143-50-0] (Vol. 20, Suppl. 7; 1987)
Chlorendic acid [115-28-6] (Vol. 48; 1990)
para-Chloroaniline [106-47-8] (Vol. 57; 1993)
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone
[77439-76-0] (Vol. 84; 2004)
Chloroform [67-66-3] (Vol. 73; 1999)
1-Chloro-2-methylpropene [513-37-1] (Vol. 63; 1995)
[Chlorophenols: see Polychlorophenols]
Chlorophenoxy herbicides (Vol. 41, Suppl. 7; 1987)
4-Chloro-ortho-phenylenediamine [95-83-0] (Vol.
27, Suppl.7; 1987)
Chloroprene [126-99-8] (Vol. 71; 1999)
Chlorothalonil [1897-45-6] (Vol. 73; 1999)
Chrysene [218-01-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
CI Acid Red 114 [6459-94-5] (Vol. 57; 1993)
CI Basic Red 9 [569-61-9] (Vol. 57, Vol. 99; in preparation)
CI Direct Blue 15 [2429-74-5] (Vol. 57; 1993)
Citrus Red No. 2 [6358-53-8] (Vol. 8, Suppl. 7; 1987)
Cobalt [7440-48-4] and cobalt compounds (Vol. 52; 1991)
(NB: Evaluated as a group)
Cobalt sulfate [10026-24-1] and other soluble cobalt(II)
salts (Vol. 86; 2006)
para-Cresidine [120-71-8] (Vol. 27, Suppl. 7; 1987)
Cycasin [14901-08-7] (Vol. 10, Suppl. 7; 1987)
Dacarbazine [4342-03-4] (Vol. 26, Suppl. 7; 1987)
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) [117-10-2]
(Vol. 50; 1990)
Daunomycin [20830-81-3] (Vol. 10, Suppl. 7; 1987)
DDT [p,p'-DDT, 50-29-3] (Vol. 53; 1991)
N,N'-Diacetylbenzidine [613-35-4] (Vol. 16,
Suppl.7; 1987)
2,4-Diaminoanisole [615-05-4] (Vol. 79; 2001)
4,4'-Diaminodiphenyl ether [101-80-4] (Vol. 29, Suppl.
7; 1987)
2,4-Diaminotoluene [95-80-7] (Vol. 16, Suppl. 7; 1987)
Dibenz[a,h]acridine [226-36-8] (Vol. 32, Suppl.
7; 1987)
Dibenz[a,j]acridine [224-42-0] (Vol. 32, Suppl.
7; 1987)
7H-Dibenzo[c,g]carbazole [194-59-2] (Vol.
32, Suppl.7; 1987)
Dibenzo[a,h]pyrene [189-64-0] (Vol. 32, Suppl. 7,
Vol. 92; in preparation)
Dibenzo[a,i]pyrene [189-55-9] (Vol. 32, Suppl. 7,
Vol. 92; in preparation)
1,2-Dibromo-3-chloropropane [96-12-8] (Vol. 20, Suppl.
7, Vol. 71; 1999)
2,3-Dibromopropan-1-ol [96-13-9] (Vol. 77; 2000)
Dichloroacetic acid [79-43-6] (Vol. 84; 2004)
para-Dichlorobenzene [106-46-7] (Vol. 73; 1999)
3,3'-Dichlorobenzidine [91-94-1] (Vol. 29, Suppl. 7; 1987)
3,3'-Dichloro-4,4'-diaminodiphenyl ether [28434-86-8] (Vol.
16,Suppl. 7; 1987)
1,2-Dichloroethane [107-06-2] (Vol. 20, Suppl. 7, Vol.
71; 1999)
Dichloromethane (methylene chloride) [75-09-2] (Vol. 71;
1999)
1,3-Dichloropropene [542-75-6] (technical-grade) (Vol.
41, Suppl.7, Vol. 71; 1999)
Dichlorvos [62-73-7] (Vol. 53; 1991)
Diepoxybutane [1464-53-5] (Vol. 11, Suppl. 7, Vol. 71, Vol. 97; 2008)
1,2-Diethylhydrazine [1615-80-1] (Vol. 4, Suppl. 7, Vol.
71; 1999)
Diglycidyl resorcinol ether [101-90-6] (Vol. 36, Suppl.
7, Vol. 71; 1999)
Dihydrosafrole [94-58-6] (Vol. 10, Suppl. 7; 1987)
Diisopropyl sulfate [2973-10-6] (Vol. 54, Vol. 71; 1999)
3,3'-Dimethoxybenzidine (ortho-Dianisidine) [119-90-4]
(Vol. 4, Suppl. 7; 1987)
para-Dimethylaminoazobenzene [60-11-7] (Vol. 8,
Suppl. 7; 1987)
trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)-vinyl]-1,3,4-oxadiazole
[25962-77-0]
(Vol. 7, Suppl. 7; 1987)
2,6-Dimethylaniline (2,6-Xylidine) [87-62-7] (Vol. 57;
1993)
3,3'-Dimethylbenzidine (ortho-Tolidine) [119-93-7]
(Vol.1, Suppl. 7; 1987)
1,1-Dimethylhydrazine [57-14-7] (Vol. 4, Suppl. 7, Vol.
71; 1999)
3,7-Dinitrofluoranthene [105735-71-5] (Vol. 65; 1996)
3,9-Dinitrofluoranthene [22506-53-2] (Vol. 65; 1996)
1,6-Dinitropyrene [42397-64-8] (Vol. 46; 1989)
1,8-Dinitropyrene [42397-65-9] (Vol. 46; 1989)
2,4-Dinitrotoluene [121-14-2] (Vol. 65; 1996)
2,6-Dinitrotoluene [606-20-2] (Vol. 65; 1996)
1,4-Dioxane [123-91-1] (Vol. 11, Suppl. 7, Vol. 71; 1999)
Disperse Blue 1 [2475-45-8] (Vol. 48; 1990)
1,2-Epoxybutane [106-88-7] (Vol. 47, Vol. 71; 1999)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Ethyl acrylate [140-88-5] (Vol. 39, Suppl. 7, Vol. 71;
1999)
Ethylbenzene [100-41-4] (Vol. 77; 2000)
Ethyl methanesulfonate [62-50-0] (Vol. 7, Suppl. 7; 1987)
[Foreign bodies: see Surgical implants and other foreign
bodies]
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole [3570-75-0]
(Vol. 7, Suppl. 7; 1987)
Fumonisin B1 [116355-83-0] (Vol. 82; 2002)
Furan [110-00-9] (Vol. 63; 1995)
Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole)
[67730-11-4] (Vol. 40, Suppl. 7; 1987)
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole)[67730-10-3]
(Vol. 40, Suppl. 7; 1987)
Glycidaldehyde [765-34-4] (Vol. 11, Suppl. 7, Vol. 71;
1999)
Griseofulvin [126-07-8] (Vol. 79; 2001)
HC Blue No. 1 [2784-94-3] (Vol. 57; 1993)
Heptachlor [76-44-8] (Vol. 79; 2001)
Hexachlorobenzene [118-74-1] (Vol. 79; 2001)
Hexachloroethane [67-72-1] (Vol. 73; 1999)
Hexachlorocyclohexanes (Vol. 20, Suppl. 7; 1987)
Hexamethylphosphoramide [680-31-9] (Vol. 15, Suppl. 7,
Vol. 71; 1999)
Human immunodeficiency virus type 2 (infection with) (Vol.
67; 1996)
Human papillomavirus types 6 and 11 (Vol. 90; 2007)
Human papillomavirus genus beta (some types) (Vol. 90;
2007)
Hydrazine [302-01-2] (Vol. 4, Suppl. 7, Vol. 71; 1999)
1-Hydroxyanthraquinone [129-43-1] (Vol. 82; 2002)
Indeno[1,2,3-cd]pyrene [193-39-5] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
Iron-dextran complex [9004-66-4] (Vol. 2, Suppl. 7; 1987)
Isoprene [78-79-5] (Vol. 60, Vol. 71; 1999)
Lasiocarpine [303-34-4] (Vol. 10, Suppl. 7; 1987)
Lead [7439-92-1] (Vol. 23, Suppl. 7; 1987)
Magenta (mixtures composed of C.I. Basic Red 9 [569-61-9],
methyl fuchsin [632-99-5], dimethyl fuchsin [26261-57-4]
or trimethyl fuchsin [3248-91-7]) (Vol. 57, Vol. 99; in
preparation)
Magnetic fields (extremely low-frequency) (Vol. 80; 2002)
MeA-a-C
(2-Amino-3-methyl-9H-pyrido[2,3-b]indole)
[68006-83-7] (Vol. 40, Suppl. 7; 1987)
Medroxyprogesterone acetate [71-58-9] (Vol. 21, Suppl.
7; 1987)
MeIQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline)
[77094-11-2] (Vol. 56; 1993)
MeIQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline)
[77500-04-0] (Vol. 56; 1993)
Merphalan [531-76-0] (Vol. 9, Suppl. 7; 1987)
2-Methylaziridine (Propyleneimine) [75-55-8] (Vol. 9, Suppl.
7, Vol. 71; 1999)
Methylazoxymethanol acetate [592-62-1] (Vol. 10, Suppl.
7; 1987)
5-Methylchrysene [3697-24-3] (Vol. 32, Suppl. 7, Vol. 92;
in preparation)
4,4'-Methylene bis(2-methylaniline) [838-88-0] (Vol. 4,
Suppl.7; 1987)
4,4'-Methylenedianiline [101-77-9] (Vol. 39, Suppl. 7;
1987)
Methylmercury compounds (Vol. 58; 1993)
(NB: Evaluated as a group)
2-Methyl-1-nitroanthraquinone [129-15-7] (uncertain purity)
(Vol.27, Suppl. 7; 1987)
N-Methyl-N-nitrosourethane [615-53-2] (Vol.
4, Suppl.7; 1987)
Methylthiouracil [56-04-2] (Vol. 79; 2001)
Metronidazole [443-48-1] (Vol. 13, Suppl. 7; 1987)
Michler's base [4,4'-methylenebis(N,N-dimethyl)benzenamine]
[101-61-1] (Vol. 27, Suppl. 7, Vol. 99; in preparation)
Michler's ketone [4,4'-bis(dimethylamino)benzophenone]
[90-94-8] (Vol. 99; in preparation)
Microcystin-LR [101043-37-2] (Vol. 94; in preparation)
(NB: Overall evaluation upgraded from 3 to 2B based on mechanistic
and other relevant data)
Mirex [2385-85-5] (Vol. 20, Suppl. 7; 1987)
Mitomycin C [50-07-7] (Vol. 10, Suppl. 7; 1987)
Mitoxantrone [65271-80-9] (Vol. 76; 2000)
Monocrotaline [315-22-0] (Vol. 10, Suppl. 7; 1987)
5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone
[3795-88-8] (Vol. 7, Suppl. 7; 1987)
Nafenopin [3771-19-5] (Vol. 24, Suppl. 7; 1987)
Naphthalene [91-20-3] (Vol. 82; 2002)
Nickel, metallic [7440-02-0] and alloys (Vol. 49; 1990)
Niridazole [61-57-4] (Vol. 13, Suppl. 7; 1987)
Nitrilotriacetic acid [139-13-9] and its salts (Vol. 73;
1999)
(NB: Evaluated as a group)
5-Nitroacenaphthene [602-87-9] (Vol. 16, Suppl. 7; 1987)
2-Nitroanisole [91-23-6] (Vol. 65; 1996)
Nitrobenzene [98-95-3] (Vol. 65; 1996)
6-Nitrochrysene [7496-02-8] (Vol. 46; 1989)
Nitrofen [1836-75-5] (technical-grade) (Vol. 30, Suppl.
7; 1987)
2-Nitrofluorene [607-57-8] (Vol. 46; 1989)
1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone [555-84-0]
(Vol.7, Suppl. 7; 1987)
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide [531-82-8]
(Vol. 7, Suppl. 7; 1987)
Nitrogen mustard N-oxide [126-85-2] (Vol. 9, Suppl.
7;1987)
Nitromethane [75-52-5] (Vol. 77; 2000)
2-Nitropropane [79-46-9] (Vol. 29, Suppl. 7, Vol. 71; 1999)
1-Nitropyrene [5522-43-0] (Vol. 46; 1989)
4-Nitropyrene [57835-92-4] (Vol. 46; 1989)
N-Nitrosodi-n-butylamine [924-16-3] (Vol.
17, Suppl.7; 1987)
N-Nitrosodiethanolamine [1116-54-7] (Vol. 17, Suppl.
7, Vol. 77; 2000)
N-Nitrosodi-n-propylamine [621-64-7] (Vol.
17, Suppl.7; 1987)
3-(N-Nitrosomethylamino)propionitrile [60153-49-3]
(Vol. 85; 2004)
N-Nitrosomethylethylamine [10595-95-6] (Vol. 17,
Suppl. 7; 1987)
N-Nitrosomethylvinylamine [4549-40-0] (Vol. 17,
Suppl. 7; 1987)
N-Nitrosomorpholine [59-89-2] (Vol. 17, Suppl. 7;
1987)
N-Nitrosopiperidine [100-75-4] (Vol. 17, Suppl.
7; 1987)
N-Nitrosopyrrolidine [930-55-2] (Vol. 17, Suppl.
7; 1987)
N-Nitrososarcosine [13256-22-9] (Vol. 17, Suppl.
7; 1987)
Ochratoxin A [303-47-9] (Vol. 56; 1993)
Oil Orange SS [2646-17-5] (Vol. 8, Suppl. 7; 1987)
Oxazepam [604-75-1] (Vol. 66; 1996)
Palygorskite (attapulgite) [12174-11-7] (long fibres, >
5 micrometres) (Vol. 68; 1997)
Panfuran S [794-93-4] (containing dihydroxymethylfuratrizine)
(Vol. 24, Suppl. 7; 1987)
Phenazopyridine hydrochloride [136-40-3] (Vol. 24, Suppl.
7; 1987)
Phenobarbital [50-06-6] (Vol. 79; 2001)
Phenolphthalein [77-09-8] (Vol. 76; 2000)
Phenoxybenzamine hydrochloride [63-92-3] (Vol. 24, Suppl.
7; 1987)
Phenyl glycidyl ether [122-60-1] (Vol. 47, Vol. 71; 1999)
Phenytoin [57-41-0] (Vol. 66; 1996)
PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine)
[105650-23-5] (Vol. 56; 1993)
Polychlorophenols and their sodium salts (mixed exposures)
(Vol. 41, Suppl. 7, Vol. 53, Vol. 71; 1999)
Ponceau MX [3761-53-3] (Vol. 8, Suppl. 7; 1987)
Ponceau 3R [3564-09-8] (Vol. 8, Suppl. 7; 1987)
Potassium bromate [7758-01-2] (Vol. 73; 1999)
Progestins (Suppl. 7; 1987)
Progestogen-only contraceptives (Vol. 72; 1999)
1,3-Propane sultone [1120-71-4] (Vol. 4, Suppl. 7, Vol.
71; 1999)
b-Propiolactone
[57-57-8] (Vol. 4, Suppl. 7, Vol. 71; 1999)
Propylene oxide [75-56-9] (Vol. 60; 1994)
Propylthiouracil [51-52-5] (Vol. 79; 2001)
Refractory ceramic fibres (Vol. 43, Vol. 81; 2002)
Riddelliine [23246-96-0] (Vol. 10, Suppl. 7, Vol. 82; 2002)
Safrole [94-59-7] (Vol. 10, Suppl. 7; 1987)
Schistosoma japonicum (infection with) (Vol. 61;
1994)
Sodium ortho-phenylphenate [132-27-4] (Vol. 73;
1999)
Special-purpose fibres such as E-glass and '475' glass
fibres (Vol. 81; 2002)
Sterigmatocystin [10048-13-2] (Vol. 10, Suppl. 7; 1987)
Streptozotocin [18883-66-4] (Vol. 17, Suppl. 7; 1987)
Styrene [100-42-5] (Vol. 60, 82; 2002)
Sulfallate [95-06-7] (Vol. 30, Suppl. 7; 1987)
Surgical implants and other foreign bodies (Vol. 74; 1999):
- Polymeric implants prepared as thin smooth film (with
the exception of poly(glycolic acid))
- Metallic implants prepared as thin smooth films
- Implanted foreign bodies of metallic cobalt, metallic
nickel and an alloy powder containing 66-67% nickel, 13-16%
chromium and 7% iron
Tetrafluoroethylene [116-14-3] (Vol. 19, Suppl. 7, Vol.
71; 1999)
Tetranitromethane [509-14-8] (Vol. 65; 1996)
Thioacetamide [62-55-5] (Vol. 7, Suppl. 7; 1987)
4,4'-Thiodianiline [139-65-1] (Vol. 27, Suppl. 7; 1987)
Titanium dioxide [13463-67-7] (Vol. 47, Vol. 93; in preparation)
Thiouracil [141-90-2] (Vol. 79; 2001)
Toluene diisocyanates [26471-62-5] (Vol. 39, Suppl. 7,
Vol. 71; 1999)
Trichlormethine (Trimustine hydrochloride) [817-09-4] (Vol.
50; 1990)
Trp-P-1 (3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole)[62450-06-0]
(Vol. 31, Suppl. 7; 1987)
Trp-P-2 (3-Amino-1-methyl-5H-pyrido[4,3-b]indole)[62450-07-1]
(Vol. 31, Suppl. 7; 1987)
Trypan blue [72-57-1] (Vol. 8, Suppl. 7; 1987)
Uracil mustard [66-75-1] (Vol. 9, Suppl. 7; 1987)
Vanadium pentoxide [1314-62-1] (Vol. 86; 2006)
Vinyl acetate [108-05-4] (Vol. 63; 1995)
4-Vinylcyclohexene [100-40-3] (Vol. 60; 1994)
4-Vinylcyclohexene diepoxide [106-87-6] (Vol. 60; 1994)
Zalcitabine [7481-89-2] (Vol. 76; 2000)
Zidovudine (AZT) [30516-87-1] (Vol. 76; 2000)
Mixtures
Bitumens [8052-42-4], extracts of steam-refined and air-refined
(Vol. 35, Suppl. 7; 1987)
Carrageenan [9000-07-1], degraded (Vol. 31, Suppl. 7; 1987)
Chlorinated paraffins of average carbon chain length C12
and average degree of chlorination approximately 60% (Vol.
48; 1990)
Coffee (urinary bladder) (Vol. 51; 1991)
(NB: There is some evidence of an inverse relationship between
coffee drinking and cancer of the large bowel; coffee drinking
could not be classified as to its carcinogenicity to other
organs)
Diesel fuel, marine (Vol. 45; 1989)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Engine exhaust, gasoline (Vol. 46; 1989)
Fuel oils, residual (heavy) (Vol. 45; 1989)
Gasoline (Vol. 45; 1989)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Pickled vegetables (traditional in Asia) (Vol. 56; 1993)
Polybrominated biphenyls [Firemaster BP-6, 59536-65-1]
(Vol. 41, Suppl. 7; 1987)
Toxaphene (Polychlorinated camphenes) [8001-35-2] (Vol.
79; 2001)
Toxins derived from Fusarium moniliforme: fumonisin
B1 and B2 and fusarin C (Vol. 56; 1993)
Welding fumes (Vol. 49; 1990)
Exposure circumstances
Carpentry and joinery (Vol. 25, Suppl. 7; 1987)
Cobalt metal without tungsten carbide (Vol. 86; 2006)
Dry cleaning (occupational exposures in) (Vol. 63; 1995)
Firefighter (occupational exposure as a) (Vol. 98; in preparation)
Printing processes (occupational exposures in) (Vol. 65;
1996)
Talc-based body powder (perineal use of) (Vol. 93; in preparation)
Textile manufacturing industry (work in) (Vol. 48; 1990)
Group 3: Not classifiable as to its carcinogenicity
to humans (515)
Agents and groups of agents
Acenaphthene [83-32-9] (Vol. 92; in preparation)
Acepyrene (3,4-dihydrocyclopenta[cd]pyrene) [25732-74-5]
(Vol. 92; in preparation)
Aciclovir [59277-89-3] (Vol. 76; 2000)
Acridine orange [494-38-2] (Vol. 16, Suppl. 7; 1987)
Acriflavinium chloride [8018-07-3] (Vol. 13, Suppl. 7;
1987)
Acrolein [107-02-8] (Vol. 63; 1995)
Acrylic acid [79-10-7] (Vol. 19, Suppl. 7, Vol. 71; 1999)
Acrylic fibres (Vol. 19, Suppl. 7; 1987)
Acrylonitrile-butadiene-styrene copolymers (Vol. 19, Suppl.
7; 1987)
Actinomycin D [50-76-0] (Vol. 10, Suppl. 7; 1987)
Agaritine [2757-90-6] (Vol. 31, Suppl. 7; 1987)
Aldicarb [116-06-3] (Vol. 53; 1991)
Aldrin [309-00-2] (Vol. 5, Suppl. 7; 1987)
Allyl chloride [107-05-1] (Vol. 36, Suppl. 7, Vol. 71;
1999)
Allyl isothiocyanate [57-06-7] (Vol. 73; 1999)
Allyl isovalerate [2835-39-4] (Vol. 36, Suppl. 7, Vol.
71; 1999)
Amaranth [915-67-3] (Vol. 8, Suppl. 7; 1987)
5-Aminoacenaphthene [4657-93-6] (Vol. 16, Suppl. 7; 1987)
2-Aminoanthraquinone [117-79-3] (Vol. 27, Suppl. 7; 1987)
para-Aminobenzoic acid [150-13-0] (Vol. 16, Suppl.
7; 1987)
1-Amino-2-methylanthraquinone [82-28-0] (Vol. 27, Suppl.
7; 1987)
2-Amino-4-nitrophenol [99-57-0] (Vol. 57; 1993)
2-Amino-5-nitrophenol [121-88-0] (Vol. 57; 1993)
4-Amino-2-nitrophenol [119-34-6] (Vol. 16, Suppl. 7; 1987)
2-Amino-5-nitrothiazole [121-66-4] (Vol. 31, Suppl. 7;
1987)
11-Aminoundecanoic acid [2432-99-7] (Vol. 39, Suppl. 7;
1987)
Amitrole [61-82-5] (Vol. 79; 2001)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
Ampicillin [69-53-4] (Vol. 50; 1990)
Anaesthetics, volatile (Vol. 11, Suppl. 7; 1987)
Angelicin [523-50-2] plus ultraviolet A radiation (Vol.
40, Suppl. 7; 1987)
Aniline [62-53-3] (Vol. 27, Suppl. 7; 1987)
para-Anisidine [104-94-9] (Vol. 27, Suppl. 7; 1987)
Anthanthrene [191-26-4] (Vol. 32, Suppl. 7, Vol. 92; in
preparation)
Anthracene [120-12-7] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Anthranilic acid [118-92-3] (Vol. 16, Suppl. 7; 1987)
Antimony trisulfide [1345-04-6] (Vol. 47; 1989)
Apholate [52-46-0] (Vol. 9, Suppl. 7; 1987)
para-Aramid fibrils [24938-64-5] (Vol. 68; 1997)
Atrazine [1912-24-9] (Vol. 73; 1999)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
Aurothioglucose [12192-57-3] (Vol. 13, Suppl. 7; 1987)
2-(1-Aziridinyl)ethanol [1072-52-2] (Vol. 9, Suppl. 7;
1987)
Aziridyl benzoquinone [800-24-8] (Vol. 9, Suppl. 7; 1987)
Azobenzene [103-33-3] (Vol. 8, Suppl. 7; 1987)
11H-Benz[bc]aceanthrylene [202-94-8] (Vol.
92; in preparation)
Benz[l]aceanthrylene [211-91-6] (Vol. 92; in preparation)
Benz[a]acridine [225-11-6] (Vol. 32, Suppl. 7; 1987)
Benz[c]acridine [225-51-4] (Vol. 32, Suppl. 7; 1987)
Benzo[b]chrysene [214-17-5] (Vol. 92; in preparation)
Benzo[g]chrysene [196-78-1] (Vol. 92; in preparation)
Benzo[a]fluoranthene [203-33-8] (Vol. 92; in preparation)
Benzo[ghi]fluoranthene [203-12-3] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
Benzo[a]fluorene [238-84-6] (Vol. 32, Suppl. 7,
Vol. 92; in preparation)
Benzo[b]fluorene [243-17-4] (Vol. 32, Suppl. 7,
Vol. 92; in preparation)
Benzo[c]fluorene [205-12-9] (Vol. 32, Suppl. 7,
Vol. 92; in preparation)
Benzo[ghi]perylene [191-24-2] (Vol. 32, Suppl. 7,
Vol. 92; in preparation)
Benzo[e]pyrene [192-97-2] (Vol. 32, Suppl. 7, Vol.
92; in preparation)
para-Benzoquinone dioxime [105-11-3] (Vol. 29, Suppl.
7, Vol. 71; 1999)
Benzoyl peroxide [94-36-0] (Vol. 36, Suppl. 7, Vol. 71;
1999)
Benzyl acetate [140-11-4] (Vol. 40, Suppl. 7, Vol. 71;
1999)
Bis(1-aziridinyl)morpholinophosphine sulfide [2168-68-5]
(Vol.9, Suppl. 7; 1987)
Bis(2-chloroethyl)ether [111-44-4] (Vol. 9, Suppl. 7, Vol.
71; 1999)
1,2-Bis(chloromethoxy)ethane [13483-18-6] (Vol. 15; Suppl.
7, Vol. 71; 1999)
1,4-Bis(chloromethoxymethyl)benzene [56894-91-8] (Vol.
15, Suppl. 7, Vol. 71; 1999)
Bis(2-chloro-1-methylethyl)ether [108-60-1] (Vol. 41, Suppl.
7, Vol. 71; 1999)
Bis(2,3-epoxycyclopentyl)ether [2386-90-5] (Vol. 47, Vol.
71; 1999)
Bisphenol A diglycidyl ether (Aralditeâ)
[1675-54-3] (Vol. 47, Vol. 71; 1999)
Bisulfites (Vol. 54; 1992)
Blue VRS [129-17-9] (Vol. 16, Suppl. 7; 1987)
Brilliant Blue FCF, disodium salt [3844-45-9] (Vol. 16,
Suppl.7; 1987)
Bromochloroacetonitrile [83463-62-1] (Vol. 52, Vol. 71;
1999)
Bromoethane [74-96-4] (Vol. 52, Vol. 71; 1999)
Bromoform [75-25-2] (Vol. 52, Vol. 71; 1999)
2-Butoxyethanol [111-76-2] (Vol. 88; 2006)
1-tert-Butoxypropan-2-ol
[57018-52-7] (Vol. 88; 2006)
n-Butyl acrylate [141-32-2] (Vol. 39, Suppl. 7,
Vol. 71; 1999)
Butylated hydroxytoluene (BHT) [128-37-0] (Vol. 40, Suppl.
7; 1987)
Butyl benzyl phthalate [85-68-7] (Vol. 73; 1999)
g-Butyrolactone [96-48-0] (Vol.
11, Suppl. 7, Vol. 71; 1999)
Caffeine [58-08-2] (Vol. 51; 1991)
Cantharidin [56-25-7] (Vol. 10, Suppl. 7; 1987)
Captan [133-06-2] (Vol. 30, Suppl. 7; 1987)
Carbaryl [63-25-2] (Vol. 12, Suppl. 7; 1987)
Carbazole [86-74-8] (Vol. 32, Suppl. 7, Vol. 71; 1999)
3-Carbethoxypsoralen [20073-24-9] (Vol. 40, Suppl. 7; 1987)
Carmoisine [3567-69-9] (Vol. 8, Suppl. 7; 1987)
Carrageenan [9000-07-1], native (Vol. 31, Suppl. 7; 1987)
Chloral [75-87-6] (Vol. 63; 1995)
Chloral hydrate [302-17-0] (Vol. 84; 2004)
Chloramine [10599-90-3] (Vol. 84; 2004)
Chlordimeform [6164-98-3] (Vol. 30, Suppl. 7; 1987)
Chlorinated drinking-water (Vol. 52; 1991)
Chloroacetonitrile [107-14-2] (Vol. 52, Vol. 71; 1999)
Chlorobenzilate [510-15-6] (Vol. 30, Suppl. 7; 1987)
Chlorodibromomethane [124-48-1] (Vol. 52, Vol. 71; 1999)
Chlorodifluoromethane [75-45-6] (Vol. 41, Suppl. 7, Vol.
71; 1999)
Chloroethane [75-00-3] (Vol. 52, Vol. 71; 1999)
Chlorofluoromethane [593-70-4] (Vol. 41, Suppl. 7, Vol.
71; 1999)
3-Chloro-2-methylpropene [563-47-3] (Vol. 63; 1995)
4-Chloro-meta-phenylenediamine [5131-60-2] (Vol.
27, Suppl.7; 1987)
Chloronitrobenzenes [88-73-3; 121-73-3; 100-00-5] (Vol.
65; 1996)
Chloropropham [101-21-3] (Vol. 12, Suppl. 7; 1987)
Chloroquine [54-05-7] (Vol. 13, Suppl. 7; 1987)
5-Chloro-ortho-toluidine [95-79-4] (Vol. 77; 2000)
2-Chloro-1,1,1-trifluoroethane [75-88-7] (Vol. 41, Suppl.
7, Vol. 71; 1999)
Cholesterol [57-88-5] (Vol. 31, Suppl. 7; 1987)
Chromium[III] compounds (Vol. 49; 1990)
Chromium [7440-47-3], metallic (Vol. 49; 1990)
Chrysoidine [532-82-1] (Vol. 8, Suppl. 7; 1987)
CI Acid Orange 3 [6373-74-6] (Vol. 57; 1993)
Cimetidine [51481-61-9] (Vol. 50; 1990)
Cinnamyl anthranilate [87-29-6] (Vol. 77; 2000)
CI Pigment Red 3 [2425-85-6] (Vol. 57; 1993)
Citrinin [518-75-2] (Vol. 40, Suppl. 7; 1987)
Clofibrate [637-07-0] (Vol. 66; 1996)
Clomiphene citrate [50-41-9] (Vol. 21, Suppl. 7; 1987)
Coal dust (Vol. 68; 1997)
Continuous glass filament (Vol. 43, Vol. 81; 2002)
Copper 8-hydroxyquinoline [10380-28-6] (Vol. 15, Suppl.
7; 1987)
Coronene [191-07-1] (Vol. 32, Suppl. 7; 1987)
Coumarin [91-64-5] (Vol. 77; 2000)
meta-Cresidine [102-50-1] (Vol. 27, Suppl. 7; 1987)
Crotonaldehyde [4170-30-3] (Vol. 63; 1995)
Cyclamates [sodium cyclamate, 139-05-9] (Vol. 73; 1999)
Cyclochlorotine [12663-46-6] (Vol. 10, Suppl. 7; 1987)
Cyclohexanone [108-94-1] (Vol. 47, Vol. 71; 1999)
4H-Cyclopenta[def]chrysene [202-98-2] (Vol.
92; in preparation)
5,6-Cyclopenteno-1,2-benzanthracene [7099-43-6] (Vol. 92;
in preparation)
D & C Red No. 9 [5160-02-1] (Vol. 57; 1993)
Dapsone [80-08-0] (Vol. 24, Suppl. 7; 1987)
Decabromodiphenyl oxide [1163-19-5] (Vol. 48, Vol. 71;
1999)
Deltamethrin [52918-63-5] (Vol. 53; 1991)
Diacetylaminoazotoluene [83-63-6] (Vol. 8, Suppl. 7; 1987)
Diallate [2303-16-4] (Vol. 30, Suppl. 7; 1987)
1,2-Diamino-4-nitrobenzene [99-56-9] (Vol. 16, Suppl. 7;
1987)
1,4-Diamino-2-nitrobenzene [5307-14-2] (Vol. 57; 1993)
2,5-Diaminotoluene [95-70-5] (Vol. 16, Suppl. 7; 1987)
Diazepam [439-14-5] (Vol. 66; 1996)
Diazomethane [334-88-3] (Vol. 7, Suppl. 7; 1987)
Dibenz[a,c]anthracene [215-58-7] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
Dibenz[a,j]anthracene [224-41-9] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
Dibenzo-para-dioxin (Vol. 69; 1997)
Dibenzo[a,e]fluoranthene [5385-75-1] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
13H-Dibenzo[a,g]fluorene [207-83-0]
(Vol. 92; in preparation)
Dibenzo[h,rst]pentaphene [192-47-2] (Vol. 3, Suppl.
7, Vol. 92; in preparation)
Dibenzo[a,e]pyrene [192-65-4] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
Dibenzo[e,l]pyrene [192-51-8] (Vol. 92; in
preparation)
Dibromoacetonitrile [3252-43-5] (Vol. 52, Vol. 71; 1999)
Dichloroacetonitrile [3018-12-0] (Vol. 52, Vol. 71; 1999)
Dichloroacetylene [7572-29-4] (Vol. 39, Suppl. 7, Vol.
71; 1999)
meta-Dichlorobenzene [541-73-1] (Vol. 73; 1999)
ortho-Dichlorobenzene [95-50-1] (Vol. 73; 1999)
trans-1,4-Dichlorobutene [110-57-6] (Vol. 15, Suppl.
7, Vol. 71; 1999)
2,6-Dichloro-para-phenylenediamine [609-20-1] (Vol.
39, Suppl. 7; 1987)
1,2-Dichloropropane [78-87-5] (Vol. 41, Suppl. 7, Vol.
71; 1999)
Dicofol [115-32-2] (Vol. 30, Suppl. 7; 1987)
Didanosine [69655-05-6] (Vol. 76; 2000)
Dieldrin [60-57-1] (Vol. 5, Suppl. 7; 1987)
Diethanolamine [111-42-2] (Vol. 77; 2000)
Di(2-ethylhexyl) adipate [103-23-1] (Vol. 77; 2000)
Di(2-ethylhexyl) phthalate [117-81-7] (Vol. 77; 2000)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
N,N'-Diethylthiourea [105-55-5] (Vol. 79;
2001)
Dihydroaceanthrylene [641-48-5] (Vol. 92; in preparation)
Dihydroxymethylfuratrizine [794-93-4] (Vol. 24, Suppl.
7; 1987)
Dimethoxane [828-00-2] (Vol. 15, Suppl. 7; 1987)
3,3'-Dimethoxybenzidine-4,4'-diisocyanate [91-93-0] (Vol.
39, Suppl. 7; 1987)
para-Dimethylaminoazobenzenediazo sodium sulfonate
[140-56-7] (Vol. 8, Suppl. 7; 1987)
4,4'-Dimethylangelicin [22975-76-4] plus ultraviolet A
radiation (Suppl. 7; 1987)
4,5'-Dimethylangelicin [4063-41-6] plus ultraviolet A radiation
(Suppl. 7; 1987)
N,N-Dimethylaniline [121-69-7] (Vol. 57;
1993)
Dimethylformamide [68-12-2] (Vol. 47; Vol. 71; 1999)
Dimethyl hydrogen phosphite [868-85-9] (Vol. 48, Vol. 71;
1999)
1,4-Dimethylphenanthrene [22349-59-3] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
1,3-Dinitropyrene [75321-20-9] (Vol. 46; 1989)
3,5-Dinitrotoluene [618-85-9] (Vol. 65; 1996)
Dinitrosopentamethylenetetramine [101-25-7] (Vol. 11, Suppl.
7; 1987)
2,4'-Diphenyldiamine [492-17-1] (Vol. 16, Suppl. 7; 1987)
Disperse Yellow 3 [2832-40-8] (Vol. 48; 1990)
Disulfiram [97-77-8] (Vol. 12, Suppl. 7; 1987)
Dithranol [1143-38-0] (Vol. 13; Suppl. 7; 1987)
Doxefazepam [40762-15-0] (Vol. 66; 1996)
Doxylamine succinate [562-10-7] (Vol. 79; 2001)
Droloxifene [82413-20-5] (Vol. 66; 1996)
Dulcin [150-69-6] (Vol. 12, Suppl. 7; 1987)
Electric fields (extremely low-frequency) (Vol. 80; 2002)
Electric fields (static) (Vol. 80; 2002)
Endrin [72-20-8] (Vol. 5, Suppl. 7; 1987)
Eosin [15086-94-9] (Vol. 15, Suppl. 7; 1987)
3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclo-hexanecarboxylate
[141-37-7]
(Vol. 11, Suppl. 7, Vol. 71; 1999)
cis-9,10-Epoxystearic acid [2443-39-2] (Vol. 11,
Suppl. 7, Vol. 71; 1999)
Estazolam [29975-16-4] (Vol. 66; 1996)
Ethionamide [536-33-4] (Vol. 13, Suppl. 7; 1987)
Ethylene [74-85-1] (Vol. 60; 1994)
Ethylene sulfide [420-12-2] (Vol. 11, Suppl. 7; 1987)
Ethylenethiourea [96-45-7] (Vol. 79; 2001)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
2-Ethylhexyl acrylate [103-11-7] (Vol. 60; 1994)
Ethyl selenac [5456-28-0] (Vol. 12, Suppl. 7; 1987)
Ethyl tellurac [20941-65-5] (Vol. 12, Suppl. 7; 1987)
Eugenol [97-53-0] (Vol. 36, Suppl. 7; 1987)
Evans blue [314-13-6] (Vol. 8, Suppl. 7; 1987)
Fast Green FCF [2353-45-9] (Vol. 16, Suppl. 7; 1987)
Fenvalerate [51630-58-1] (Vol. 53; 1991)
Ferbam [14484-64-1] (Vol. 12, Suppl. 7; 1987)
Ferric oxide [1309-37-1] (Vol. 1, Suppl. 7; 1987)
Fluometuron [2164-17-2] (Vol. 30, Suppl. 7; 1987)
Fluoranthene [206-44-0] (Vol. 32, Suppl. 7, Vol. 92; in
preparation)
Fluorene [86-73-7] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Fluorescent lighting (Vol. 55; 1992)
Fluorides (inorganic, used in drinking-water) (Vol. 27,
Suppl.7; 1987)
5-Fluorouracil [51-21-8] (Vol. 26, Suppl. 7; 1987)
[Foreign bodies: see Surgical implants and other foreign
bodies]
Furazolidone [67-45-8] (Vol. 31, Suppl. 7; 1987)
Furfural [98-01-1] (Vol. 63; 1995)
Furosemide (Frusemide) [54-31-9] (Vol. 50; 1990)
Gemfibrozil [25812-30-0] (Vol. 66; 1996)
Glycidyl oleate [5431-33-4] (Vol. 11, Suppl. 7; 1987)
Glycidyl stearate [7460-84-6] (Vol. 11, Suppl. 7; 1987)
Guinea Green B [4680-78-8] (Vol. 16, Suppl. 7; 1987)
Gyromitrin [16568-02-8] (Vol. 31, Suppl. 7; 1987)
Haematite [1317-60-8] (Vol. 1, Suppl. 7; 1987)
HC Blue No. 2 [33229-34-4] (Vol. 57; 1993)
HC Red No. 3 [2871-01-4] (Vol. 57; 1993)
HC Yellow No. 4 [59820-43-8] (Vol. 57; 1993)
Hepatitis D virus (Vol. 59; 1994)
Hexachlorobutadiene [87-68-3] (Vol. 73; 1999)
Hexachlorophene [70-30-4] (Vol. 20, Suppl. 7; 1987)
Human T-cell lymphotropic virus type II (Vol. 67; 1996)
Hycanthone mesylate [23255-93-8] (Vol. 13, Suppl. 7; 1987)
Hydralazine [86-54-4] (Vol. 24, Suppl. 7; 1987)
Hydrochloric acid [7647-01-0] (Vol. 54; 1992)
Hydrochlorothiazide [58-93-5] (Vol. 50; 1990)
Hydrogen peroxide [7722-84-1] (Vol. 36, Suppl. 7, Vol.
71; 1999)
Hydroquinone [123-31-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)
4-Hydroxyazobenzene [1689-82-3] (Vol. 8, Suppl. 7; 1987)
8-Hydroxyquinoline [148-24-3] (Vol. 13, Suppl. 7; 1987)
Hydroxysenkirkine [26782-43-4] (Vol. 10, Suppl. 7; 1987)
Hydroxyurea [127-07-1] (Vol. 76; 2000)
Hypochlorite salts (Vol. 52; 1991)
Insulation glass wool (Vol. 43, Vol. 81; 2002)
Iron-dextrin complex [9004-51-7] (Vol. 2, Suppl. 7; 1987)
Iron sorbitol-citric acid complex [1338-16-5] (Vol. 2,
Suppl. 7; 1987)
Isatidine [15503-86-3] (Vol. 10, Suppl. 7; 1987)
Isonicotinic acid hydrazide (Isoniazid) [54-85-3] (Vol.
4, Suppl.7; 1987)
Isophosphamide [3778-73-2] (Vol. 26, Suppl. 7; 1987)
Isopropanol [67-63-0] (Vol. 15, Suppl. 7, Vol. 71; 1999)
Isopropyl oils (Vol. 15, Suppl. 7, Vol. 71; 1999)
Isosafrole [120-58-1] (Vol. 10, Suppl. 7; 1987)
Jacobine [6870-67-3] (Vol. 10, Suppl. 7; 1987)
Kaempferol [520-18-3] (Vol. 31, Suppl. 7; 1987)
Kojic acid [501-30-4] (Vol. 79; 2001)
Lauroyl peroxide [105-74-8] (Vol. 36, Suppl. 7, Vol. 71;
1999)
Lead compounds, organic (Vol. 23, Suppl. 7, Vol. 87; 2006)
(NB: Organic lead compounds are metabolized, at least in
part, to ionic lead both in humans and animals. To the extent
that ionic lead, generated from organic lead, is present
in the body, it will be expected to exert the toxicities
associated with inorganic lead.)
Light Green SF [5141-20-8] (Vol. 16, Suppl. 7; 1987)
d-Limonene [5989-27-5] (Vol. 73; 1999)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
Luteoskyrin [21884-44-6] (Vol. 10, Suppl. 7; 1987)
Madder root (Rubia tinctorum) (Vol. 82; 2002)
Magnetic fields (static) (Vol. 80; 2002)
Malathion [121-75-5] (Vol. 30, Suppl. 7; 1987)
Maleic hydrazide [123-33-1] (Vol. 4, Suppl. 7; 1987)
Malonaldehyde [542-78-9] (Vol. 36, Suppl. 7, Vol. 71; 1999)
Maneb [12427-38-2] (Vol. 12, Suppl. 7; 1987)
Mannomustine dihydrochloride [551-74-6] (Vol. 9, Suppl.
7; 1987)
Medphalan [13045-94-8] (Vol. 9, Suppl. 7; 1987)
Melamine [108-78-1] (Vol. 73; 1999)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
6-Mercaptopurine [50-44-2] (Vol. 26, Suppl. 7; 1987)
Mercury [7439-97-6] and inorganic mercury compounds (Vol.
58; 1993)
Metabisulfites (Vol. 54; 1992)
Methimazole [60-56-0] (Vol. 79; 2001)
Methotrexate [59-05-2] (Vol. 26, Suppl. 7; 1987)
Methoxychlor [72-43-5] (Vol. 20, Suppl. 7; 1987)
Methyl acrylate [96-33-3] (Vol. 39, Suppl. 7, Vol. 71;
1999)
5-Methylangelicin [73459-03-7] plus ultraviolet A radiation
(Suppl.7; 1987)
Methyl bromide [74-83-9] (Vol. 41, Suppl. 7, Vol. 71; 1999)
Methyl tert-butyl ether [1634-04-4] (Vol. 73; 1999)
Methyl carbamate [598-55-0] (Vol. 12, Suppl. 7; 1987)
Methyl chloride [74-87-3] (Vol. 41, Suppl. 7, Vol. 71;
1999)
1-Methylchrysene [3351-28-8] (Vol. 32, Suppl. 7, Vol. 92;
in preparation)
2-Methylchrysene [3351-32-4] (Vol. 32, Suppl. 7, Vol. 92;
in preparation)
3-Methylchrysene [3351-31-3] (Vol. 32, Suppl. 7, Vol. 92;
in preparation)
4-Methylchrysene [3351-30-2] (Vol. 32, Suppl. 7, Vol. 92;
in preparation)
6-Methylchrysene [1705-85-7] (Vol. 32, Suppl. 7, Vol. 92;
in preparation)
N-Methyl-N,4-dinitrosoaniline [99-80-9] (Vol.
1, Suppl. 7; 1987)
4,4'-Methylenediphenyl diisocyanate [101-68-8] (Vol. 19,
Suppl. 7, Vol. 71; 1999)
2-Methylfluoranthene [33543-31-6] (Vol. 32, Suppl. 7, Vol.
92; in preparation)
3-Methylfluoranthene [1706-01-0] (Vol. 32, Suppl. 7, Vol.
92; in preparation)
Methylglyoxal [78-98-8] (Vol. 51; 1991)
Methyl iodide [74-88-4] (Vol. 41, Suppl. 7, Vol. 71; 1999)
Methyl methacrylate [80-62-6] (Vol. 60; 1994)
N-Methylolacrylamide [90456-67-0] (Vol. 60; 1994)
Methyl parathion [298-00-0] (Vol. 30, Suppl. 7; 1987)
1-Methylphenanthrene [832-69-9] (Vol. 32, Suppl. 7, Vol.
92; in preparation)
7-Methylpyrido[3,4-c]psoralen [85878-63-3] (Vol.
40, Suppl.7; 1987)
Methyl red [493-52-7] (Vol. 8, Suppl. 7; 1987)
Methyl selenac [144-34-3] (Vol. 12, Suppl. 7; 1987)
Microcystis extracts (Vol. 94; in preparation)
Modacrylic fibres (Vol. 19, Suppl. 7; 1987)
Monuron [150-68-5] (Vol. 53; 1991)
Morpholine [110-91-8] (Vol. 47, Vol. 71; 1999)
Musk ambrette [83-66-9] (Vol. 65; 1996)
Musk xylene [81-15-2] (Vol. 65; 1996)
1,5-Naphthalenediamine [2243-62-1] (Vol. 27, Suppl. 7;
1987)
1,5-Naphthalene diisocyanate [3173-72-6] (Vol. 19, Suppl.
7, Vol. 71; 1999)
Naphtho[1,2-b]fluoranthene [111189-32-3] (Vol. 92;
in preparation)
Naphtho[2,1-a]fluoranthene [203-20-3] (Vol. 92;
in preparation)
Naphtho[2,3-e]pyrene [193-09-9] (Vol. 92; in preparation)
1-Naphthylamine [134-32-7] (Vol. 4, Suppl. 7; 1987)
1-Naphthylthiourea (ANTU) [86-88-4] (Vol. 30, Suppl. 7;
1987)
Nithiazide [139-94-6] (Vol. 31, Suppl. 7; 1987)
5-Nitro-ortho-anisidine [99-59-2] (Vol. 27, Suppl.
7; 1987)
9-Nitroanthracene [602-60-8] (Vol. 33, Suppl. 7; 1987)
7-Nitrobenz[a]anthracene [20268-51-3] (Vol. 46;
1989)
6-Nitrobenzo[a]pyrene [63041-90-7] (Vol. 46; 1989)
4-Nitrobiphenyl [92-93-3] (Vol. 4, Suppl. 7; 1987)
3-Nitrofluoranthene [892-21-7] (Vol. 33, Suppl. 7; 1987)
Nitrofural (Nitrofurazone) [59-87-0] (Vol. 50; 1990)
Nitrofurantoin [67-20-9] (Vol. 50; 1990)
1-Nitronaphthalene [86-57-7] (Vol. 46; 1989)
2-Nitronaphthalene [581-89-5] (Vol. 46; 1989)
3-Nitroperylene [20589-63-3] (Vol. 46; 1989)
2-Nitropyrene [789-07-1] (Vol. 46; 1989)
N'-Nitrosoanabasine (NAB) [37620-20-5] (Vol. 37,
Suppl. 7, Vol. 89; 2007)
N'-Nitrosoanatabine (NAT) [71267-22-6] (Vol. 37,
Suppl. 7, Vol. 89; 2007)
N-Nitrosodiphenylamine [86-30-6] (Vol. 27, Suppl.
7; 1987)
para-Nitrosodiphenylamine [156-10-5] (Vol. 27, Suppl.
7; 1987)
N-Nitrosofolic acid [29291-35-8] (Vol. 17, Suppl.
7; 1987)
N-Nitrosoguvacine [55557-01-2] (Vol. 85; 2004)
N-Nitrosoguvacoline [55557-02-3] (Vol. 85; 2004)
N-Nitrosohydroxyproline [30310-80-6] (Vol. 17, Suppl.
7; 1987)
3-(N-Nitrosomethylamino)propionaldehyde [85502-23-4]
(Vol. 85; 2004)
N-Nitrosoproline [7519-36-0] (Vol. 17, Suppl. 7;
1987)
Nitrotoluenes [88-72-2; 99-08-1; 99-99-0] (Vol. 65; 1996)
5-Nitro-ortho-toluidine [99-55-8] (Vol. 48; 1990)
Nitrovin [804-36-4] (Vol. 31, Suppl. 7; 1987)
Nodularins [118399-22-7] (Vol. 94; in preparation)
Nylon 6 [25038-54-4] (Vol. 19, Suppl. 7; 1987)
Oestradiol mustard [22966-79-6] (Vol. 9, Suppl. 7; 1987)
Opisthorchis felineus (infection with) (Vol. 61;
1994)
Orange I [523-44-4] (Vol. 8, Suppl. 7; 1987)
Orange G [1936-15-8] (Vol. 8, Suppl. 7; 1987)
Oxyphenbutazone [129-20-4] (Vol. 13, Suppl. 7; 1987)
Palygorskite (attapulgite) [12174-11-7] (short fibres,
< 5 micrometres) (Vol. 68; 1997)
Paracetamol (Acetaminophen) [103-90-2] (Vol. 73; 1999)
Parasorbic acid [10048-32-5] (Vol. 10, Suppl. 7; 1987)
Parathion [56-38-2] (Vol. 30, Suppl. 7; 1987)
Patulin [149-29-1] (Vol. 40, Suppl. 7; 1987)
Penicillic acid [90-65-3] (Vol. 10, Suppl. 7; 1987)
Pentachloroethane [76-01-7] (Vol. 41, Suppl. 7, Vol. 71;
1999)
Permethrin [52645-53-1] (Vol. 53; 1991)
Perylene [198-55-0] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Petasitenine [60102-37-6] (Vol. 31, Suppl. 7; 1987)
Phenanthrene [85-01-8] (Vol. 32, Suppl. 7, Vol. 92; in
preparation)
Phenelzine sulfate [156-51-4] (Vol. 24, Suppl. 7; 1987)
Phenicarbazide [103-03-7] (Vol. 12, Suppl. 7; 1987)
Phenol [108-95-2] (Vol. 47, Vol. 71; 1999)
Phenylbutazone [50-33-9] (Vol. 13, Suppl. 7; 1987)
meta-Phenylenediamine [108-45-2] (Vol. 16, Suppl.
7; 1987)
para-Phenylenediamine [106-50-3] (Vol. 16, Suppl.
7; 1987)
N-Phenyl-2-naphthylamine [135-88-6] (Vol. 16, Suppl.
7;1987)
ortho-Phenylphenol [90-43-7] (Vol. 73; 1999)
Picene [213-46-7] (Vol. 92; in preparation)
Picloram [1918-02-1] (Vol. 53; 1991)
Piperonyl butoxide [51-03-6] (Vol. 30, Suppl. 7; 1987)
Polyacrylic acid [9003-01-4] (Vol. 19, Suppl. 7; 1987)
Polychlorinated dibenzo-para-dioxins (other than
2,3,7,8-tetrachlorodibenzo-para-dioxin) (Vol. 69;
1997)
Polychlorinated dibenzofurans (Vol. 69; 1997)
Polychloroprene [9010-98-4] (Vol. 19, Suppl. 7; 1987)
Polyethylene [9002-88-4] (Vol. 19, Suppl. 7; 1987)
Polymethylene polyphenyl isocyanate [9016-87-9] (Vol. 19,
Suppl.7; 1987)
Polymethyl methacrylate [9011-14-7] (Vol. 19, Suppl. 7;
1987)
Polypropylene [9003-07-0] (Vol. 19, Suppl. 7; 1987)
Polystyrene [9003-53-6] (Vol. 19, Suppl. 7; 1987)
Polytetrafluoroethylene [9002-84-0] (Vol. 19, Suppl. 7;
1987)
Polyurethane foams [9009-54-5] (Vol. 19, Suppl. 7; 1987)
Polyvinyl acetate [9003-20-7] (Vol. 19, Suppl. 7; 1987)
Polyvinyl alcohol [9002-89-5] (Vol. 19, Suppl. 7; 1987)
Polyvinyl chloride [9002-86-2] (Vol. 19, Suppl. 7; 1987)
Polyvinyl pyrrolidone [9003-39-8] (Vol. 19, Suppl. 7, Vol.
71; 1999)
Ponceau SX [4548-53-2] (Vol. 8, Suppl. 7; 1987)
Potassium bis(2-hydroxyethyl)dithiocarbamate [23746-34-1]
(Vol. 12, Suppl. 7; 1987)
Prazepam [2955-38-6] (Vol. 66; 1996)
Prednimustine [29069-24-7] (Vol. 50; 1990)
Prednisone [53-03-2] (Vol. 26, Suppl. 7; 1987)
Proflavine salts (Vol. 24, Suppl. 7; 1987)
Pronetalol hydrochloride [51-02-5] (Vol. 13, Suppl. 7;
1987)
Propham [122-42-9] (Vol. 12, Suppl. 7; 1987)
n-Propyl carbamate [627-12-3] (Vol. 12, Suppl. 7;
1987)
Propylene [115-07-1] (Vol. 60; 1994)
Ptaquiloside [87625-62-5] (Vol. 40, Suppl. 7; 1987)
Pyrene [129-00-0] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Pyridine [110-86-1] (Vol. 77; 2000)
Pyrido[3,4-c]psoralen [85878-62-2] (Vol. 40, Suppl.
7; 1987)
Pyrimethamine [58-14-0] (Vol. 13, Suppl. 7; 1987)
Quercetin [117-39-5] (Vol. 73; 1999)
para-Quinone [106-51-4] (Vol. 15, Suppl. 7, Vol.
71; 1999)
Quintozene (Pentachloronitrobenzene) [82-68-8] (Vol. 5,
Suppl. 7; 1987)
Reserpine [50-55-5] (Vol. 24, Suppl. 7; 1987)
Resorcinol [108-46-3] (Vol. 15, Suppl. 7, Vol. 71, 1999)
Retrorsine [480-54-6] (Vol. 10, Suppl. 7; 1987)
Rhodamine B [81-88-9] (Vol. 16, Suppl. 7; 1987)
Rhodamine 6G [989-38-8] (Vol. 16, Suppl. 7; 1987)
Rifampicin [13292-46-1] (Vol. 24, Suppl. 7; 1987)
Ripazepam [26308-28-1] (Vol. 66; 1996)
Rock (stone) wool (Vol. 43, Vol. 81; 2002)
Rugulosin [23537-16-8] (Vol. 40, Suppl. 7; 1987)
Saccharated iron oxide [8047-67-4] (Vol. 2, Suppl. 7; 1987)
Saccharin [81-07-2] and its salts (Vol. 73; 1999)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
Scarlet Red [85-83-6] (Vol. 8, Suppl. 7; 1987)
Schistosoma mansoni (infection with) (Vol. 61; 1994)
Selenium [7782-49-2] and selenium compounds (Vol. 9, Suppl.
7; 1987)
Semicarbazide hydrochloride [563-41-7] (Vol. 12, Suppl.
7; 1987)
Seneciphylline [480-81-9] (Vol. 10, Suppl. 7; 1987)
Senkirkine [2318-18-5] (Vol. 31, Suppl. 7; 1987)
Sepiolite [15501-74-3] (Vol. 68; 1997)
Shikimic acid [138-59-0] (Vol. 40, Suppl. 7; 1987)
Silica [7631-86-9], amorphous (Vol. 68; 1997)
Simazine [122-34-9] (Vol. 73; 1999)
Slag wool (Vol. 43, Vol. 81; 2002)
Sodium chlorite [7758-19-2] (Vol. 52; 1991)
Sodium diethyldithiocarbamate [148-18-5] (Vol. 12, Suppl.
7; 1987)
Spironolactone [52-01-7] (Vol. 79; 2001)
Styrene-acrylonitrile copolymers [9003-54-7] (Vol. 19,
Suppl.7; 1987)
Styrene-butadiene copolymers [9003-55-8] (Vol. 19, Suppl.
7; 1987)
Succinic anhydride [108-30-5] (Vol. 15, Suppl. 7; 1987)
Sudan I [842-07-9] (Vol. 8, Suppl. 7; 1987)
Sudan II [3118-97-6] (Vol. 8, Suppl. 7; 1987)
Sudan III [85-86-9] (Vol. 8, Suppl. 7; 1987)
Sudan Brown RR [6416-57-5] (Vol. 8, Suppl. 7; 1987)
Sudan Red 7B [6368-72-5] (Vol. 8, Suppl. 7; 1987)
Sulfafurazole (Sulfisoxazole) [127-69-5] (Vol. 24, Suppl.
7; 1987)
Sulfamethazine [57-68-1] (Vol. 79; 2001)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
Sulfamethoxazole [723-46-6] (Vol. 79; 2001)
Sulfites (Vol. 54; 1992)
Sulfur dioxide [7446-09-5] (Vol. 54; 1992)
Sunset Yellow FCF [2783-94-0] (Vol. 8, Suppl. 7; 1987)
Surgical implants and other foreign bodies (Vol. 74; 1999):
- Organic polymeric materials (as a group)
- Orthopaedic implants of complex composition
- Cardiac pacemakers
- Silicone breast implants
- Implanted foreign bodies of metallic chromium or titanium
and of cobalt-based, chromium-based and titanium-based alloys,
stainless steel and depleted uranium
- Dental materials
- Ceramic implants
Symphytine [22571-95-5] (Vol. 31, Suppl. 7; 1987)
Talc [14807-96-6], not containing asbestiform fibres (inhaled)
(Vol. 42, Suppl. 7, Vol. 93; in preparation)
Tannic acid [1401-55-4] and tannins (Vol. 10, Suppl. 7;
1987)
Temazepam [846-50-4] (Vol. 66; 1996)
2,2',5,5'-Tetrachlorobenzidine [15721-02-5] (Vol. 27, Suppl.
7; 1987)
1,1,1,2-Tetrachloroethane [630-20-6] (Vol. 41, Suppl. 7,
Vol. 71; 1999)
1,1,2,2-Tetrachloroethane [79-34-5] (Vol. 20, Suppl. 7,
Vol. 71; 1999)
Tetrachlorvinphos [22248-79-9] (Vol. 30, Suppl. 7; 1987)
Tetrakis(hydroxymethyl)phosphonium salts (Vol. 48, Vol.
71; 1999)
Theobromine [83-67-0] (Vol. 51; 1991)
Theophylline [58-55-9] (Vol. 51; 1991)
Thiourea [62-56-6] (Vol. 79; 2001)
Thiram [137-26-8] (Vol. 53; 1991)
Toluene [108-88-3] (Vol. 47, Vol. 71; 1999)
Toremifene [89778-26-7] (Vol. 66; 1996)
Toxins derived from Fusarium graminearum, F.
culmorum and F. crookwellense: zearalenone, deoxynivalenol,
nivalenol and fusarenone X (Vol. 56; 1993)
Toxins derived from Fusarium sporotrichioides: T-2
toxin (Vol. 56; 1993)
Trichlorfon [52-68-6] (Vol. 30, Suppl. 7; 1987)
Trichloroacetic acid [76-03-9] (Vol. 84; 2004)
Trichloroacetonitrile [545-06-2] (Vol. 52, Vol. 71; 1999)
1,1,1-Trichloroethane [71-55-6] (Vol. 20, Suppl. 7, Vol.
71; 1999)
1,1,2-Trichloroethane [79-00-5] (Vol. 52, Vol. 71; 1999)
Triethanolamine [102-71-6] (Vol. 77; 2000)
Triethylene glycol diglycidyl ether [1954-28-5] (Vol. 11,
Suppl. 7, Vol. 71; 1999)
Trifluralin [1582-09-8] (Vol. 53; 1991)
4,4',6-Trimethylangelicin [90370-29-9] plus ultraviolet
A radiation (Suppl. 7; 1987)
2,4,5-Trimethylaniline [137-17-7] (Vol. 27, Suppl. 7; 1987)
2,4,6-Trimethylaniline [88-05-1] (Vol. 27, Suppl. 7; 1987)
4,5',8-Trimethylpsoralen [3902-71-4] (Vol. 40, Suppl. 7;
1987)
2,4,6-Trinitrotoluene [118-96-7] (Vol. 65; 1996)
Triphenylene [217-59-4] (Vol. 32, Suppl. 7, Vol. 92; in
preparation)
Tris(aziridinyl)-para-benzoquinone (Triaziquone)
[68-76-8] (Vol. 9, Suppl. 7; 1987)
Tris(1-aziridinyl)phosphine oxide [545-55-1] (Vol. 9, Suppl.
7; 1987)
2,4,6-Tris(1-aziridinyl)-s-triazine [51-18-3] (Vol.
9,Suppl. 7; 1987)
Tris(2-chloroethyl) phosphate [115-96-8] (Vol. 48, Vol.
71; 1999)
1,2,3-Tris(chloromethoxy)propane [38571-73-2] (Vol. 15,
Suppl. 7, Vol. 71; 1999)
Tris(2-methyl-1-aziridinyl)phosphine oxide [57-39-6] (Vol.
9, Suppl. 7; 1987)
Vat Yellow 4 [128-66-5] (Vol. 48; 1990)
Vinblastine sulfate [143-67-9] (Vol. 26, Suppl. 7; 1987)
Vincristine sulfate [2068-78-2] (Vol. 26, Suppl. 7; 1987)
Vinyl chloride-vinyl acetate copolymers [9003-22-9] (Vol.
19, Suppl. 7; 1987)
Vinylidene chloride [75-35-4] (Vol. 39, Suppl. 7, Vol.
71; 1999)
Vinylidene chloride-vinyl chloride copolymers [9011-06-7]
(Vol.19, Suppl. 7; 1987)
Vinylidene fluoride [75-38-7] (Vol. 39, Suppl. 7, Vol.
71; 1999)
N-Vinyl-2-pyrrolidone [88-12-0] (Vol. 19, Suppl.
7, Vol. 71; 1999)
Vinyl toluene [25013-15-4] (Vol. 60; 1994)
Vitamin K [12001-79-5] substances (Vol. 76; 2000)
Wollastonite [13983-17-0] (Vol. 68; 1997)
Xylenes [1330-20-7] (Vol. 47, Vol. 71; 1999)
2,4-Xylidine [95-68-1] (Vol. 16, Suppl. 7; 1987)
2,5-Xylidine [95-78-3] (Vol. 16, Suppl. 7; 1987)
Yellow AB [85-84-7] (Vol. 8, Suppl. 7; 1987)
Yellow OB [131-79-3] (Vol. 8, Suppl. 7; 1987)
Zectran [315-18-4] (Vol. 12, Suppl. 7; 1987)
Zeolites [1318-02-1] other than erionite (clinoptilolite,
phillipsite,mordenite, non-fibrous Japanese zeolite, synthetic
zeolites) (Vol.68; 1997)
Zineb [12122-67-7] (Vol. 12, Suppl. 7; 1987)
Ziram [137-30-4] (Vol. 53; 1991)
Mixtures
Bitumens [8052-42-4], steam-refined, cracking-residue and
air-refined (Vol. 35, Suppl. 7; 1987)
Crude oil [8002-05-9] (Vol. 45; 1989)
Diesel fuels, distillate (light) (Vol. 45; 1989)
Fuel oils, distillate (light) (Vol. 45; 1989)
Jet fuel (Vol. 45; 1989)
Mate (Vol. 51; 1991)
Mineral oils, highly-refined (Vol. 33, Suppl. 7; 1987)
Petroleum solvents (Vol. 47; 1989)
Printing inks (Vol. 65; 1996)
Tea (Vol. 51; 1991)
Terpene polychlorinates (Strobane®) [8001-50-1]
(Vol. 5, Suppl. 7; 1987)
Exposure circumstances
Calcium carbide production (Vol. 92; in preparation)
Flat-glass and specialty glass (manufacture of) (Vol. 58;
1993)
Hair colouring products (personal use of) (Vol. 57, Vol.
99; in preparation)
Leather goods manufacture (Vol. 25, Suppl. 7; 1987)
Leather tanning and processing (Vol. 25, Suppl. 7; 1987)
Lumber and sawmill industries (including logging) (Vol.
25, Suppl.7; 1987)
Paint manufacture (occupational exposure in) (Vol. 47;
1989)
Pulp and paper manufacture (Vol. 25, Suppl. 7; 1987)
Group 4: Probably not carcinogenic to humans (1)
Caprolactam [105-60-2] (Vol. 39, Suppl. 7, Vol. 71; 1998)
Last updated: 16 January 2009
|